Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

IPCA Laboratories: Firing on All Cylinders

Entero Healthcare: The Hidden MedTech Opportunity

Jana Small Finance Bank: From Repair To Re-Acceleration

Inox India Ltd: Backbone For Industrial Gases And Clean Energy

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.</li>
<li>The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.</li>
<li>The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.</li>
</ul>


Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.
The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.
The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.


Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform